| Drug | Indication | Research | IND enabling | Phase 1 (Oncology) | Phase 1 (Autoimmune) |
|---|---|---|---|---|---|
| CND106 (BCMAxCD3) Antibody |
Autoantibody diseases (e.g. myasthenia gravis) | ||||
| CND261 (CD20xCD3) Antibody |
Autoimmune diseases (e.g. RA) | ||||
| Not disclosed | Autoimmune and other | ||||
| Research | IND enabling | Phase 1 (Oncology) | Phase 1 (Autoimmune) |
| CND106 (BCMAxCD3) Antibody | |||
| Autoantibody diseases (e.g. myasthenia gravis) | |||
| CND261 (CD20xCD3) Antibody | |||
| Autoimmune diseases (e.g. RA) | |||
| Not disclosed | |||
| Autoimmune and other | |||
CND106 (BCMAxCD3) Antibody
CND106 is a BCMAxCD3 bispecific antibody designed to target and eliminate later stage B-cells which are responsible for producing harmful autoantibodies. While Anti-FcRn therapies have shown promise in treating autoantibody-driven diseases, emerging clinical evidence suggests that targeting BCMA can lead to deeper and more effective responses compared to Anti-FcRn therapies. Having successfully completed a Phase 1 dose escalation study in oncology patients, CND106 is now being developed by Candid for potential use in autoimmune diseases.
CND261 (CD20xCD3) Antibody
CND261 is a CD20xCD3 bispecific antibody designed to target a broad range of B-cell subtypes, from pro B-cells to plasmablasts/plasma cells. While several CD20-based antibodies have already demonstrated clinical benefit in various autoimmune conditions, CND261’s unique T-cell engager technology has the potential to significantly enhance efficacy. Having successfully completed a Phase 1 dose escalation study in oncology patients, Candid is now developing CND261 to address unmet needs in autoimmune diseases.